These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 10860092

  • 1. Prostate cancer in Victoria in 1993: patterns of reported management.
    Frydenberg M, Giles GG, Mameghan H, Thursfield VJ, Millar J, Wheelahan JB, Bolton DM, Syme RR.
    Med J Aust; 2000 Mar 20; 172(6):270-4. PubMed ID: 10860092
    [Abstract] [Full Text] [Related]

  • 2. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
    Zietman AL, Thakral H, Wilson L, Schellhammer P.
    J Urol; 2001 Nov 20; 166(5):1702-6. PubMed ID: 11586206
    [Abstract] [Full Text] [Related]

  • 3. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackmaan S, Moul JW.
    J Clin Oncol; 2003 Nov 01; 21(21):4001-8. PubMed ID: 14581423
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS, Goel V, Williams JI, Iscoe NA.
    CMAJ; 1999 Jan 12; 160(1):70-5. PubMed ID: 9934349
    [Abstract] [Full Text] [Related]

  • 5. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL, SEARCH Database Study Group.
    J Urol; 2003 Jun 12; 169(6):2129-35. PubMed ID: 12771734
    [Abstract] [Full Text] [Related]

  • 6. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H.
    BJU Int; 2005 Apr 12; 95(6):751-6. PubMed ID: 15794776
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D.
    BJU Int; 2005 May 12; 95(7):956-60. PubMed ID: 15839912
    [Abstract] [Full Text] [Related]

  • 9. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ, Sun L, Kane CJ, Presti JC, Terris MK, Amling CL, Moul JW, Aronson WJ.
    BJU Int; 2008 Sep 12; 102(8):969-74. PubMed ID: 18691175
    [Abstract] [Full Text] [Related]

  • 10. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing.
    Okihara K, Nakanishi H, Nakamura T, Mizutani Y, Kawauchi A, Miki T.
    Int J Urol; 2005 Jul 12; 12(7):662-7. PubMed ID: 16045559
    [Abstract] [Full Text] [Related]

  • 11. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.
    Jones JS, Follis HW, Johnson JR.
    Prostate Cancer Prostatic Dis; 2009 Jul 12; 12(1):57-60. PubMed ID: 18379587
    [Abstract] [Full Text] [Related]

  • 12. Prostate biopsy: who, how and when. An update.
    Djavan B, Milani S, Remzi M.
    Can J Urol; 2005 Feb 12; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR.
    Cancer; 2008 Jun 15; 112(12):2664-70. PubMed ID: 18433013
    [Abstract] [Full Text] [Related]

  • 16. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A.
    BJU Int; 2007 Jan 15; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [Abstract] [Full Text] [Related]

  • 17. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC, SEARCH Database Study Group.
    J Urol; 2003 Jun 15; 169(6):2136-41. PubMed ID: 12771735
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.